|本期目录/Table of Contents|

非酒精性脂肪性肝病与消化道肿瘤的相关研究进展

《现代肿瘤医学》[ISSN:1672-4992/CN:61-1415/R]

期数:
2021年01期
页码:
149-154
栏目:
综述
出版日期:
2020-11-30

文章信息/Info

Title:
Research progress of non-alcoholic fatty liver disease and gastrointestinal tumors
作者:
王 洁1; 曹亚萍1; 刘 娟1; 祁 莹1; 吕欢欢1; 时永全1; 2
1.西安医学院，陕西 西安 710021;2.空军军医大学西京医院消化内科，陕西 西安 710032
Author(s):
WANG Jie1; CAO Yaping1; LIU Juan1; QI Ying1; LYU Huanhuan1; SHI Yongquan1; 2
1.Xi'an Medical University，Shaanxi Xi'an 710021，China；2.Department of Gastroenterology，Xijing Hospital，Air Force Military Medical University，Shaanxi Xi'an 710032，China.
关键词:
非酒精性脂肪性肝病; 食管癌; 胃癌; 结直肠癌; 胰岛素抵抗; 脂肪因子; 肠道微生态
Keywords:
non-alcoholic fatty liver disease; esophageal cancer; gastric cancer; colorectal cancer; insulin resistance; adipokines; gut microbiota
分类号:
R735
DOI:
10.3969/j.issn.1672-4992.2021.01.034
文献标识码:
A
摘要:
非酒精性脂肪性肝病（NAFLD）是代谢综合征的肝脏表现，易合并心脑血管疾病、内分泌疾病、慢性肾脏病、阻塞性睡眠呼吸暂停综合征、骨质疏松症等肝外疾病，近年来众多研究发现NAFLD患者多种肝外恶性肿瘤患病率增高，并以消化道肿瘤患病率最高，本文就NAFLD与消化道肿瘤的相关研究进展及其可能的分子机制进行综述。
Abstract:
Non-alcoholic fatty liver disease (NAFLD) is the liver manifestation of metabolic syndrome，which is easy to be combined with cardio-cerebrovascular disease，endocrine disease，chronic kidney disease，obstructive sleep apnea syndrome，osteoporosis and other extrahepatic diseases.In recent years，many studies have found that the prevalence of multiple extrahepatic malignant tumors in NAFLD patients increased，with the highest incidence of gastrointestinal tumors.This article reviews the progress of the studies on the correlation between NAFLD and gastrointestinal tumors and the underlying molecular mechanisms of tumorigenesis.

参考文献/References

［1］KOUZU K，TSUJIMOTO H，NISHIKAWA M，et al.Risk factors for nonalcoholic fatty liver disease after gastrectomy for gastric cancer［J］.Gastric Cancer，2020，23(2)：356-362.
［2］VELARDE-RUIZ VJ，GARCíA-JIMéN，GARCíA-ZERMEO KR，et al.Complicaciones extrahepáticas de la enfermedad por hígado graso no alcohólico：impacto más allá del hígado［J］.Revista de Gastroenterología de México，2019，84(4)：472-481.
［3］ARMSTRONG MJ，ADAMS LA，CANBAY A，et al.Extrahepatic complications of nonalcoholic fatty liver disease［J］.Hepatology，2014，59(3)：1174-1197.
［4］CALORI G，LATTUADA G，RAGOGNA F，et al.Fatty liver index(FLI) and mortality：The cremona study at the 15th year of follow-up［J］.Diabetes，2011，54(1)：145-152.
［5］KWAK MS，YIM JY，YI A，et al.Non-alcoholic fatty liver disease is associated with breast cancer in nonobese women［J］.Dig Liver Dis，2019，51(7)：1030-1035.
［6］SANNA C，ROSSO C，MARIETTI M，et al.Non-alcoholic fatty liver disease and extra-hepatic cancers［J］.Int J Mol Sci，2016，17(5)：717.
［7］Global Burden of Disease Cancer，FITZMAURICE C，ALLEN C，et al.Global，regional，and national cancer incidence，mortality，years of life lost，years lived with disability，and disability-adjusted life-years for 32 cancer groups，1990 to 2015：A systematic analysis for the global burden of disease study［J］.JAMA Oncol，2017，3(4)：524-548.
［8］HUANG FL，YU SJ.Esophageal cancer：Risk factors，genetic association，and treatment［J］.Asian J Surg，2018，41(3)：210-215.
［9］SINGH S，SHARMA AN，MURAD MH，et al.Central adiposity is associated with increased risk of esophageal inflammation，metaplasia，and adenocarcinoma：A systematic review and meta-analysis［J］.Clinical Gastroenterology and Hepatology，2013，11(11)：1399-1412,e7.
［10］EL-SERAG HB，ERGUN GA，PANDOLFINO J，et al.Obesity increases oesophageal acid exposure［J］.Gut，2007，56(6)：749-755.
［11］KUBO A，COOK MB，SHAHEEN NJ，et al.Sex-specific associations between body mass index，waist circumference and the risk of Barrett's oesophagus：A pooled analysis from the international BEACON consortium［J］.Gut，2013，62(12)：1684-1691.
［12］HE Q，LI JD，HUANG W，et al.Metabolic syndrome is associated with increased risk of Barrett esophagus：A meta-analysis［J］.Medicine(Baltimore)，2016，95(31)：e4338.
［13］LEE JM，PARK YM，YUN JS，et al.The association between nonalcoholic fatty liver disease and esophageal，stomach，or colorectal cancer：National population-based cohort study［J］.PLoS One，2020，15(1)：e0226351.
［14］ASHKTORAB H，KUPFER SS，BRIM H，et al.Racial disparity in gastrointestinal cancer risk［J］.Gastroenterology，2017，153(4)：910-923.
［15］HE Z，ZHAO TT，XU HM，et al.Association between alcohol consumption and the risk of gastric cancer：a meta-analysis of prospective cohort studies［J］.Oncotarget，2017，8(48)：84459-84472.
［16］UZEL M，SAHINER Z，FILIK L.Non-alcoholic fatty liver disease，metabolic syndrome and gastric cancer：Single center experience［J］.Journal of Buon，2015，20(2)：662.
［17］HAMAGUCHI M，HASHIMOTO Y，OBORA A，et al.Non-alcoholic fatty liver disease with obesity as an independent predictor for incident gastric and colorectal cancer：A population-based longitudinal study［J］.BMJ Open Gastroenterology，2019，6(1)：e000295.
［18］ALLEN AM，HICKS SB，MARA KC，et al.The risk of incident extrahepatic cancers is higher in non-alcoholic fatty liver disease than obesity:A longitudinal cohort study［J］.J Hepatol，2019，71(6)：1229-1236.
［19］FERLAY J，SOERJOMATARAM I，DIKSHIT R，et al.Cancer incidence and mortality worldwide：sources，methods and major patterns in GLOBOCAN 2012［J］.Int J Cancer，2015，136(5)：E359-386.
［20］LEE YI，LIM YS，PARK HS.Colorectal neoplasms in relation to non-alcoholic fatty liver disease in Korean women：a retrospective cohort study［J］.J Gastroenterol Hepatol，2012，27(1)：91-95.
［21］KIM GA，LEE HC，CHOE J，et al.Association between non-alcoholic fatty liver disease and cancer incidence rate［J］.J Hepatol，2018，68(1)：140-146.
［22］AHN JS，SINN DH，MIN YW，et al.Non-alcoholic fatty liver diseases and risk of colorectal neoplasia［J］.Aliment Pharmacol Ther，2017，45(2)：345-353.
［23］CHO Y，LIM SK，JOO SK，et al.Nonalcoholic steatohepatitis is associated with a higher risk of advanced colorectal neoplasm［J］.Liver International，2019，39(9)：1722-1731.
［24］SHI X，ZHANG J，MO L，et al.Efficacy and safety of probiotics in eradicating Helicobacter pylori：A network meta-analysis［J］.J Medicine,2019，98(15)：e15180.
［25］SALTIEL AR，KAHN CR.Insulin signalling and the regulation of glucose and lipid metabolism［J］.Nature，2001，414(6865)：799-806.
［26］TAM CS，XIE W，JOHNSON WD，et al.Defining insulin resistance from hyperinsulinemic-euglycemic clamps［J］.Diabetes Care，2012，35(7)：1605-1610.
［27］PARK SE，PARK CY，SWEENEY G.Biomarkers of insulin sensitivity and insulin resistance：Past，present and future［J］.Crit Rev Clin Lab Sci，2015，52(4)：180-190.
［28］LI AQ，QIU MZ，ZHOU HB，et al.PTEN，insulin resistance and cancer［J］.Curr Pharm Design，2017，23(25)：3667-3676.
［29］MCKAY MM，MORRISON DK.Integrating signals from RTKs to ERK/MAPK［J］.Oncogene，2007，26(22)：3113-3121.
［30］CHIAVARINA B，WHITAKER-MENEZES D，MIGNECO G，et al.HIF1-alpha functions as a tumor promoter in cancer-associated fibroblasts，and as a tumor suppressor in breast cancer cells［J］.Cell Cycle，2010，9(17)：3534-3551.
［31］SEKO Y，SUMIDA Y，TANAKA S，et al.Insulin resistance increases the risk of incident type 2 diabetes mellitus in patients with non-alcoholic fatty liver disease［J］.Hepatol Res，2018，48(3)：E42-E51.
［32］LI C，LI J，WU D，et al.The involvement of survivin in insulin-like growth factor 1-induced epithelial-mesenchymal transition in gastric cancer［J］.Tumour Biol，2016，37(1)：1091-1096.
［33］KASPRZAK A，ADAMEK A.Insulin-like growth factor 2 (IGF2) signaling in colorectal cancer-from basic research to potential clinical applications［J］.Int J Mol Sci，2019，20(19)：4915.
［34］YALINBAS EE，BINAY C，SIMSEK E，et al.The role of umbilical cord blood concentration of IGF-1，IGF-2，leptin，adiponectin，ghrelin，resistin，and visfatin in fetal growth［J］.American Journal of Perinatology，2019，36(6)：600-608.
［35］DE KORT S，SIMONS C，VAN DEN BRANDT PA，et al.Diabetes mellitus，genetic variants in the insulin-like growth factor pathway and colorectal cancer risk［J］.Int J Cancer，2019，145(7)：1774-1781.
［36］CAMBLIN AJ，PACE EA，ADAMS S，et al.Dual inhibition of IGF-1R and ErbB3 enhances the activity of gemcitabine and nab-paclitaxel in preclinical models of pancreatic cancer［J］.Clin Cancer Res，2018，24(12)：2873-2885.
［37］GONG Y，DOU LJ，LIANG J.Link between obesity and cancer：Role of triglyceride/free fatty acid cycling［J］.Eur Rev Med Pharmacol Sci，2014，18(19)：2808-2820.
［38］ROSE DP，VONA-DAVIS L.The cellular and molecular mechanisms by which insulin influences breast cancer risk and progression［J］.Endocr-Relat Cancer，2012，19(6)：R225-R241.
［39］LI SR，NG CF，BANERJEA A，et al.Differential expression patterns of the insulin-like growth factor 2 gene in human colorectal cancer［J］.Tumour Biol，2004，25(1/2)：62-68.
［40］WARREN RS，YUAN H，MATLI MR，et al.Induction of vascular endothelial growth factor by insulin-like growth factor 1 in colorectal carcinoma［J］.J Biol Chem，1996，271(46)：29483-29488.
［41］HODGE DR，HURT EM，FARRAR WL.The role of IL-6 and STAT3 in inflammation and cancer［J］.Eur J Cancer，2005，41(16)：2502-2512.
［42］KASZAA.IL-1 and EGF regulate expression of genes important in inflammation and cancer［J］.Cytokine，2013，62(1)：22-33.
［43］SETHI G，SHANMUGAM MK，RAMACHANDRAN L，et al.Multifaceted link between cancer and inflammation［J］.Biosci Rep，2012，32(1)：1-15.
［44］CHUNG YC，CHANG YF.Serum interleukin-6 levels reflect the disease status of colorectal cancer［J］.Journal of Surgical Oncology，2003，83(4)：222-226.
［45］BAO B，ALI S，AHMAD A，et al.Hypoxia-induced aggressiveness of pancreatic cancer cells is due to increased expression of VEGF，IL-6 and miR-21，which can be attenuated by CDF treatment［J］.Plos One，2012，7(12)：12.
［46］WU Y，ZHOU BP.TNF-alpha/NF-kappa B/Snail pathway in cancer cell migration and invasion［J］.British Journal of Cancer，2010，102(4)：639-644.
［47］ROUBERT A，GREGORY K，LI Y，et al.The influence of tumor necrosis factor-alpha on the tumorigenic Wnt-signaling pathway in human mammary tissue from obese women［J］.Oncotarget，2017，8(22)：36127-36136.
［48］ZAGOZDA M，SARNECKA AK，STASZCZAK Z，et al.Correlation of TNF-alpha and TGF-beta polymorphisms with protein levels in pancreatic ductal adenocarcinoma and colorectal cancer［J］.Contemp Oncol(Pozn)，2019，23(4)：214-219.
［49］LOBIONDA S，SITTIPO P，KWON HY，et al.The role of gut microbiota in intestinal inflammation with respect to diet and extrinsic stressors［J］.Microorganisms，2019，7(8)：17.
［50］AL BATAINEH MT，DASH NR，LASSEN PB，et al.Revealing links between gut microbiome and its fungal community in type 2 diabetes mellitus among emirati subjects：A pilot study［J］.Scientific Reports，2020，10(1)：9624.
［51］MIURA K，OHNISHI H.Role of gut microbiota and Toll-like receptors in nonalcoholic fatty liver disease［J］.World J Gastroenterol，2014，20(23)：7381-7391.
［52］SUN J，KATO I.Gut microbiota，inflammation and colorectal cancer［J］.Genes Dis，2016，3(2)：130-143.
［53］SIGNORETTI M，ROGGIOLANI R，STORNELLO C，et al.Gut microbiota and pancreatic diseases［J］.Minerva Gastroenterol Dietol，2017，63(4)：399-410.
［54］ADOLPH TE，GRANDER C，GRABHERR F，et al.Adipokines and non-alcoholic fatty liver disease：multiple interactions［J］.Int J Mol Sci，2017，18(8)：1649.
［55］ZHAO CC，CHEN J，NIU RF，et al.Increased resistin suggests poor prognosis and promotes development of lung adenocarcinoma［J］.Oncology Reports，2018，40(6)：3392-3404.
［56］SERRADILLA M，OLIVER GJR，PALOMARES CA，et al.Metabolic syndrome，non-alcoholic fatty liver disease and hepatocarcinoma［J］.Revista Espaola de Enfermedades Digestivas，2020，112(2)：133-138.
［57］OLLBERDING NJ，KIM Y，SHVETSOV YB，et al.Prediagnostic leptin，adiponectin，c-reactive protein，and the risk of postmenopausal breast cancer［J］.Cancer Prevention Research，2013，6(3)：188-195.
［58］FAZOLINI NP，CRUZ AL，WERNECK MB，et al.Leptin activation of mTOR pathway in intestinal epithelial cell triggers lipid droplet formation，cytokine production and increased cell proliferation［J］.Cell Cycle，2015，14(16)：2667-2676.
［59］WANG D，CHEN J，CHEN H，et al.Leptin regulates proliferation and apoptosis of colorectal carcinoma through PI3K/Akt/mTOR signalling pathway［J］.J Biosci，2012，37(1)：91-101.
［60］LEE KN，CHOI HS，YANG SY，et al.The role of leptin in gastric cancer：Clinicopathologic features and molecular mechanisms［J］.Biochemical and Biophysical Research Communications，2014，446(4)：822-829.
［61］DONG Z，FU S，XU X，et al.Leptin-mediated regulation of ICAM-1 is Rho/ROCK dependent and enhances gastric cancer cell migration［J］.British Journal of Cancer，2014，110(7)：1801-1810.
［62］THRIFT AP.Determination of risk for Barrett's esophagus and esophageal adenocarcinoma［J］.Curr Opin Gastroenterol，2016，32(4)：319-324.
［63］OTANI K，ISHIHARA S，YAMAGUCHI H，et al.Adiponectin and colorectal cancer［J］.Surg Today，2017，47(2)：151-158.
［64］XIE L，WANG Y，WANG S，et al.Adiponectin induces growth inhibition and apoptosis in cervical cancer HeLa cells［J］.Biologia，2011，66(4)：712-720.
［65］YAMAUCHI T，KADOWAKI T.Adiponectin receptor as a key player in healthy longevity and obesity-related diseases［J］.Cell Metabolism，2013，17(2)：185-196.
［66］KUKLA M，CIUPINSKA-KAJOR M，KAJOR M，et al.Liver visfatin expression in morbidly obese patients with nonalcoholic fatty liver disease undergoing bariatric surgery［J］.Pol J Pathol，2010，61(3)：147-153.
［67］FAZELI MS，DASHTI H，AKBARZADEH S，et al.Circulating levels of novel adipocytokines in patients with colorectal cancer［J］.Cytokine，2013，62(1)：81-85.
［68］MOSCHEN AR，KASER A，ENRICH B，et al.Visfatin，an adipocytokine with proinflammatory and immunomodulating properties［J］.J Immunol，2007，178(3)：1748-1758.
［69］AUGUET T，TERRA X，PORRAS JA，et al.Plasma visfatin levels and gene expression in morbidly obese women with associated fatty liver disease［J］.Clin Biochem，2013，46(3)：202-208.
［70］MOHAMMADI M，MIANABADI F，MEHRAD-MAJD H.Circulating visfatin levels and cancers risk：A systematic review and meta-analysis［J］.Journal of Cellular Physiology，2019，234(4)：5011-5022.
［71］FAZELI MS，KERAMATI MR，RAHIMI A，et al.Visfatin level in patients with colorectal adenoma［J］.Med J Islam Repub Iran，2016，30(1)：320.
［72］HUANG WS，CHEN CN，SZE CI，et al.Visfatin induces stromal cell-derived factor-1 expression by beta1 integrin signaling in colorectal cancer cells［J］.J Cell Physiol，2013，228(5)：1017-1024.
［73］OOI SQ，CHAN RME，POH LKS，et al.Visfatin and its genetic variants are associated with obesity-related morbidities and cardiometabolic risk in severely obese children［J］.Pediatric Obesity，2014，9(2)：81-91.
［74］GENC H，DOGRU T，KARA M，et al.Association of plasma visfatin with hepatic and systemic inflammation in nonalcoholic fatty liver disease［J］.Ann Hepatol，2013，12(4)：548-555.
［75］TSAI HC，CHENG SP，HAN CK，et al.Resistin enhances angiogenesis in osteosarcoma via the MAPK signaling pathway［J］.Aging-US，2019，11(21)：9767-9777.
［76］SOGABE M，OKAHISA T，KIMURA T，et al.Influence of metabolic syndrome on upper gastrointestinal disease［J］.Clin J Gastroenterol，2016，9(4)：191-202.
［77］SINGH S，CHOUHAN S，MOHAMMAD N，et al.Resistin causes G1 arrest in colon cancer cells through upregulation of SOCS3［J］.FEBS Letters，2017，591(10)：1371-1382.
［78］SENATES E，COLAK Y，YESIL A，et al.Circulating resistin is elevated in patients with non-alcoholic fatty liver disease and is associated with steatosis，portal inflammation，insulin resistance and nonalcoholic steatohepatitis scores［J］.Minerva Med，2012，103(5)：369-376.

备注/Memo

备注/Memo:
National Natural Science Foundation of China（No.81873554）;国家自然科学基金项目（编号：81873554）；陕西省科技创新团队项目（编号：2018TD-003）
更新日期/Last Update: 2020-11-30